What is the appropriate dosing schedule, baseline laboratory and ECG monitoring, contraindications, and dose‑adjustment guidelines for ribociclib in an adult with hormone‑receptor‑positive, HER2‑negative advanced breast cancer receiving endocrine therapy?

Ribociclib Dosing and Monitoring in HR+/HER2- Advanced Breast Cancer

Standard Dosing Schedule

Ribociclib is administered at 600 mg orally once daily for 21 consecutive days followed by 7 days off, in repeating 28-day cycles, in combination with endocrine therapy. 1

• The 21-days-on/7-days-off schedule distinguishes ribociclib from abemaciclib (which uses continuous daily dosing) 2
• Dose reductions to 400 mg and then 200 mg are permitted for toxicity management while maintaining efficacy 1, 3
• Exposure-efficacy analyses demonstrate no apparent relationship between ribociclib dose and progression-free survival or overall survival, supporting the effectiveness of dose reductions when needed 3, 4

Baseline Laboratory and ECG Monitoring Requirements

Pre-Treatment Assessment

Complete blood count, comprehensive metabolic panel including liver function tests, and electrocardiogram with QTcF interval measurement must be obtained before initiating ribociclib. 1

• QTcF prolongation is dose-dependent: mean increase of 22-24 ms with aromatase inhibitors/fulvestrant, and 35 ms with tamoxifen at steady-state 1
• Baseline hepatic function assessment is critical because ribociclib undergoes extensive hepatic metabolism via CYP3A4 1
• Neutropenia occurs in 61-63.5% of patients (grade 3/4), making baseline blood counts essential 5

On-Treatment Monitoring

Obtain complete blood count on day 14 of the first two cycles, then at the beginning of each subsequent cycle for the first 6 cycles, and as clinically indicated thereafter. 1, 6

• Liver function tests should be monitored every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, then as clinically indicated 1
• ECG monitoring should be performed at approximately day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated 1
• More frequent monitoring is required with moderate hepatic impairment or when combined with tamoxifen due to greater QTcF prolongation 1

Absolute Contraindications

Ribociclib is contraindicated in patients with baseline QTcF >450 ms or severe hepatic impairment (Child-Pugh class C). 1

• Strong CYP3A inhibitors (e.g., ritonavir) increase ribociclib exposure 3.2-fold and must be avoided 1
• Strong CYP3A inducers (e.g., rifampicin) decrease ribociclib exposure by 89% and eliminate efficacy 1
• Severe renal impairment and ESRD increase ribociclib exposure 3.8-fold and 2.7-fold (AUC and Cmax, respectively), requiring dose adjustment 1

Dose Adjustment Guidelines

For Neutropenia

Grade 3 neutropenia (ANC 500-1000/mm³): Continue current dose if no fever or infection; interrupt if fever or infection develops, resume at same dose when ANC ≥1000/mm³ 6

Grade 4 neutropenia (ANC <500/mm³): Interrupt ribociclib until recovery to ANC ≥1000/mm³, then resume at reduced dose (600→400→200 mg) 1, 6

For QTcF Prolongation

QTcF >480 ms but ≤500 ms: Interrupt ribociclib, correct electrolyte abnormalities, resume at reduced dose when QTcF returns to <481 ms 1

QTcF >500 ms: Permanently discontinue ribociclib 1

For Hepatotoxicity

Grade 2 ALT/AST elevation (>3-5× ULN): Continue at current dose with increased monitoring 1

Grade 3 ALT/AST elevation (>5-20× ULN): Interrupt until recovery to ≤Grade 1, resume at reduced dose 1, 6

Grade 4 ALT/AST elevation (>20× ULN): Permanently discontinue ribociclib 1

Critical Clinical Pitfalls

Do not combine ribociclib with moderate or strong CYP3A inhibitors (including grapefruit juice) or inducers, as these cause clinically significant exposure changes. 1

• Mild hepatic impairment (Child-Pugh A) requires no dose adjustment, but moderate impairment (Child-Pugh B) increases exposure by 28-44% and requires careful monitoring 1
• Ribociclib inhibits CYP3A at the 600 mg dose, increasing exposure of CYP3A substrates and requiring dose adjustments of concomitant medications 1, 4
• The 7-day treatment break is essential for hematologic recovery and should not be shortened 2
• Electrolyte abnormalities (hypokalemia, hypomagnesemia) must be corrected before initiating therapy and maintained throughout treatment to minimize QTcF prolongation risk 1